Baloxavir
- Generic Name
- Baloxavir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H19F2N3O4S
- CAS Number
- 1985605-59-1
- Unique Ingredient Identifier
- 4G86Y4JT3F
- Background
Baloxavir is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3000
- Registration Number
- NCT05648448
- Locations
- 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Insight Therapeutics, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT05012189
- Locations
- 🇺🇸
Insight Therapeutics, LLC, Norfolk, Virginia, United States
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bassett Healthcare
- Target Recruit Count
- 60
- Registration Number
- NCT04327791
- Locations
- 🇺🇸
Bassett Medical Center, Cooperstown, New York, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.